



NEW YORK STATE SENATOR  
Brad Hoylman-Sigal

## Senator Brad Hoylman Participates In COVID-19 Vaccine Trial, Urges New Yorkers To Join

BRAD HOYLMAN-SIGAL August 6, 2020

| ISSUE: **CORONAVIRUS PANDEMIC; COVID-19, VACCINES, CORONAVIRUS; PUBLIC HEALTH, SD 27**, **SENATOR BRAD HOYLMAN**

NEW YORK, NY – New York State Senator Brad Hoylman (D/WF-Manhattan) this week began participating in a phase 3 clinical trial for a vaccine candidate to prevent COVID-19 through the NYU Grossman School of Medicine, under the auspices of NYU Langone Health's Vaccine Center. NYU Langone Health's Vaccine Center will be conducting several COVID-19 vaccine trials in conjunction with the national COVID-19 Prevention Network (CoVPN).



According to immunologists, without a vaccine for COVID-19, there will always be a risk that new outbreaks of the disease will emerge.

**Senator Hoylman said:** “The development of a COVID-19 vaccine is our generation’s moonshot. As a staunch advocate for science-based health policy to combat vaccine-preventable illnesses, I’m proud to have done my part by joining a clinical trial for a COVID-19 vaccine at the Vaccine Center at NYU Langone Health. If this or other vaccine candidates are successful, we’ll be able to stem the human suffering caused by COVID-19, protect our front-

line workers and vulnerable New Yorkers from infection, and hopefully soon resume our daily lives.

The stakes couldn't be higher. That's why we need all hands on deck to end this pandemic. I urge New Yorkers to find out whether they qualify to join a COVID-19 vaccine trial. More information is available at the Vaccine Center ([covid\\_vaccine\\_study@nyulangone.org](mailto:covid_vaccine_study@nyulangone.org)) and at [coronaviruspreventionnetwork.org](https://coronaviruspreventionnetwork.org)."

According to NYU Langone Health, if the ongoing studies are successful and the vaccine candidate receives regulatory approval, it is expected that the manufacturer will produce up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021.